Document Detail

Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate.
MedLine Citation:
PMID:  16823826     Owner:  NLM     Status:  MEDLINE    
Low-molecular-weight heparins are widely employed in prophylactic and therapeutic antithrombotic regimens for venous thromboembolic events. Excessive anticoagulation with low-molecular-weight heparins rarely can precipitate catastrophic bleeding complications. Currently, there is no specific or reliable antidote that can reverse the anticoagulant effects of low-molecular-weight heparins efficiently and safely. This report describes three individuals with underlying hypercoagulable states, who developed clinically significant bleeding complications while receiving therapeutic anticoagulation with enoxaparin. All of the hemorrhagic events subsequently were safely and effectively reversed with a single intravenous bolus infusion of recombinant activated factor VIIa (RFVIIa) concentrate. Hemoglobins, prothrombin times, and clinical overt bleeding were monitored before and after the administration of RFVIIa. In all three cases, bleeding was controlled without an increase in thrombotic events. Our findings demonstrate that RFVIIa can rapidly and safely reverse the hemorrhagic adverse effects associated with excessive levels of low-molecular-weight heparin in patients with pre-existing hypercoagulable conditions and/or acute venous thromboembolism.
Kashif Firozvi; Ruby Anne E Deveras; Craig M Kessler
Related Documents :
16047856 - Comparison of two therapeutic protocols in patients with antiphospholipid antibodies an...
3970846 - Placental transport of low molecular weight heparin in the pregnant sheep.
15118296 - Successful pregnancy in a patient with double outlet left ventricle after a rastelli op...
25162986 - Exposure to psychosocial job strain during pregnancy and odds of asthma and atopic derm...
21279936 - The association between second-trimester maternal serum alpha-fetoprotein in 14-22 week...
16298276 - Reproductive performance of pubertal red deer (cervus elaphus) hinds: effects of geneti...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  American journal of hematology     Volume:  81     ISSN:  0361-8609     ISO Abbreviation:  Am. J. Hematol.     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-08-14     Completed Date:  2007-10-09     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7610369     Medline TA:  Am J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  582-9     Citation Subset:  IM    
Division of Hematology/Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Toxicity
Factor VII / therapeutic use*
Factor VIIa
Hemorrhage / chemically induced*,  drug therapy*,  etiology
Heparin / administration & dosage,  adverse effects*
Injections, Intravenous
Middle Aged
Molecular Weight
Recombinant Proteins / therapeutic use
Risk Factors
Thrombophilia / blood,  complications*,  drug therapy*,  etiology
Treatment Outcome
Reg. No./Substance:
0/Recombinant Proteins; 0/recombinant FVIIa; 9001-25-6/Factor VII; 9005-49-6/Heparin; EC VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single...
Next Document:  All-trans retinoic acid induces p62DOK1 and p56DOK2 expression which enhances induced differentiatio...